CERO — CERo Therapeutics Holdings Cashflow Statement
0.000.00%
Last trade - 00:00- $4.75m
- $5.05m
Annual cashflow statement for CERo Therapeutics Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -11.8 | -7.29 |
| Depreciation | ||
| Non-Cash Items | 0.941 | 0.499 |
| Unusual Items | ||
| Other Non-Cash Items | ||
| Changes in Working Capital | -1.3 | 0.54 |
| Change in Prepaid Expenses | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Change in Other Liabilities | ||
| Cash from Operating Activities | -11.7 | -5.79 |
| Capital Expenditures | -0.694 | 0 |
| Purchase of Fixed Assets | ||
| Cash from Investing Activities | -0.694 | 0 |
| Financing Cash Flow Items | 0 | -0.039 |
| Other Financing Cash Flow | ||
| Net Issuance / Retirement of Stock | ||
| Net Issuance / Retirement of Debt | ||
| Cash from Financing Activities | 0.006 | 0.572 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | -12.4 | -5.22 |